Glucocorticoids (GC), like dexamethasone and prednisolone, are widely used in medicine, but how do they actually work?

This is really impressive work (Auger et al.), which figured it all out

There are two mechanisms: a slow, broad response, which depends on transcriptional…

🚨📝 A pragmatic guide for management of adverse events associated with lorlatinib
Link here 👉lungcancerjournal.info/article/S0169-…

#LCSM ALK Positive

“When I first heard my diagnosis, I spent a lot of time trying to understand if I did it to myself. Having these test results back gave me a sense of relief that there was no one to blame' - Kat

Find out how simple blood tests are changing cancer care👇
norththamesgenomics.nhs.uk/circulating-tu…

Great to see ⁦BBC News (UK)⁩ picking up this important good news story for lung cancer patients in England

You can hear more about the pilot phase of this work at ⁦⁦BTOG⁩ conference next month

⁦Sanjay Popat⁩ bbc.co.uk/news/health-68…

Resources to support 6-mercaptopurine dosing, based on TPMT/NUDT15 genotype, for ADULT Acute Lymphoblastic Leukaemia patients now available via UKCPA website for local adaptation/governance approval ukclinicalpharmacy.org/communities/ge… BOPA Committee Dharmisha Chauhan JessicaKPharmacist Hayley Wickens

This will be a good one for gynae-oncology pharmacists! Free to join.

Our next lunch-and-learn webinar is on 'Circulating Tumour DNA (ctDNA) Testing'. Professor Alastair Greystoke will discuss the progress that has been made in adopting this testing across the NHS (Tuesday 20th February, 12.30pm – 1.30pm).
Register now at: re-url.uk/WU07

Integrating rare genetic variants into #DPYD #pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity
nature.com/articles/s4139…

Looking forward to hearing Dharmisha Chauhan discuss #Pharmacogenomics at the PM Healthcare Commissioning & High Cost Drugs Conference in London on 28 February. Secure your place to hear this and much more! pmhealthcare.co.uk/events/2024/2/…

Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line bit.ly/3NldJQE

The FDA could soon approve Iovance’s lifileucel for melanoma, a much-anticipated milestone for the 35-year-old T cell therapy modality - read more in this news feature published today

The world of EGFR...simple but not so simple in 2023 ! New strategies like FLAURA2 and MARIPOSA and still many questions ! Great talk by Pilar Garrido ESMO - Eur. Oncology

🧬We've launched a new genetic biobank in collaboration with
Genomics England to study if our genes affect the side effects we experience from medicines #MedSafetyWeek

Phase 1 will look at Allopurinol and rare, related severe skin reactions bit.ly/3QQE3UX

After a pregnant woman with melanoma received pembrolizumab therapy, severe autoimmune enteritis developed in her healthy newborn infant. The condition was treated with prednisolone and infliximab NEJM OncoAlert
nej.md/3FLQhYD nej.md/3FLQhYD

Uncommon EGFR mutations (UCM) are associated with a poorer prognosis (OS, RFS) after surgery, compared with common EGFR mutations.

Tumors with UCM exhibit a higher TMB, an increased TP53 mutation frequency, and an enhanced T-cell-inflamed gene signature.

bit.ly/462GTuk

British South Asian ancestry participants views of #pharmacogenomics clinical implementation and research: a thematic analysis

nature.com/articles/s4139…

Pls join us & spread the word! UKONS Surrey and Sussex Cancer Alliance NHS Kent and Medway Cancer Alliance South East London Cancer Alliance North East London Cancer Alliance RMPartnersNHS Sarah Adomah Verna Lavender Mary Tanay RN PhD Mark Foulkes🏳️‍🌈 (He, Him) Breast Cancer Now SuzannahF

#ESMO23 Immunotherapy Orals🔥

Association btwn irAEs & OS in >9000pts tx w atezo/atezo-based thx:

- g1-2 irAE assoc w ⬆️OS (HR 0.65, p<0.05)
- *specific irAEs by grade assoc w OS:
- g3+ pneumonitis/colitis assoc w ⬇️OS
- g1-2 thyroid/derm/pneumonitis assoc ⬆️w OS

ESMO - Eur. Oncology

💊 Now we have efficacy data on PAN-KRAS inhibitor

RMC-6236 is a First-in-Class, RAS-MULTI (ON) Inhibitor

💥 ORR 38%, including 1 CR (n=40) for non-KRASG12C NSCLC

Just wow! KRASKickers

#LCSM #ESMO23

🤔FLAURA-2 CNS results #ESMO23 Osi is supposed to have good brain penetrance. Addition of chemo increases brain RR in EGFR pts
🙋Is it because it increases brain delivery of osi or it targets osi resistant / persister cells in the brain ?
👍Anyway, impactful data. OncoAlert

ALINA

Adjuvant Alectinib versus Chemo in resected ALK+ NSCLC

💥 Alectinib DFS HR 0.24
🧠 Metástasis protection

A new SOC to implement tomorrow in the clinic.

Takes chemo out of the equation in adjuvant?

Great presentation by Ben Solomon

#LCSM

#ESMO23 ESMO - Eur. Oncology